Pharmacokinetics and pharmacodynamics of meropenem in children with severe infection

International Journal of Antimicrobial Agents

Volumn 48, Issue 2, 2016, Pages 151-157

  Kongthavonsakul, Kritsana ^a   Lucksiri, Aroonrut ^b   Eakanunkul, Suntara ^b   Roongjang, Somjing ^b   Issaranggoon na Ayuthaya, Satja ^a   Oberdorfer, Peninnah ^a  

^a Faculty of Medicine Chiang Mai University   (Thailand)

^b CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

Children; Meropenem; Pharmacodynamics; Pharmacokinetics; Severe infection

Indexed keywords

MEROPENEM; ANTIINFECTIVE AGENT; THIENAMYCIN DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ARTICLE; CENTRAL VOLUME OF DISTRIBUTION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; ENTEROBACTERIACEAE; FEMALE; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PERIPHERAL VOLUME OF DISTRIBUTION; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SCHOOL CHILD; SEPSIS; SIMULATION; CHEMISTRY; COMPUTER SIMULATION; CRITICAL ILLNESS; DRUG EFFECTS; ENTEROBACTERIACEAE INFECTIONS; INTRAVENOUS DRUG ADMINISTRATION; MICROBIAL SENSITIVITY TEST; PSEUDOMONAS INFECTIONS; SERUM; TIME FACTOR;

ADMINISTRATION, INTRAVENOUS; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; COMPUTER SIMULATION; CRITICAL ILLNESS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SERUM; THIENAMYCINS; TIME FACTORS;

EID: 84979680829     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2016.04.025     Document Type: Article

References (23)

1. [1] Nicolau, D.P., Pharmacokinetic and pharmacodynamics properties of meropenem. Clin Infect Dis 47:Suppl. 1 (2008), S32–40.
2. [2] WHO Expert Committee, The selection and use of essential medicines. World Health Organ Tech Rep Ser 958 (2009), 1–242.
3. [3] Mohr, J.F., Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections. Clin Infect Dis 47:Suppl. 1 (2008), S41–51.
4. [4] Drusano, G.L., Antimicrobial pharmacodynamics: critical interactions of ‘bug and drug’. Nat Rev Microbiol 2 (2004), 289–300.
5. [5] Hurst, M., Lamb, H.M., Meropenem: a review of its use in patients in intensive care. Drugs 59 (2000), 653–680.
6. [6] Pinder, M., Bellomo, R., Lipman, J., Pharmacological principles of antibiotic prescription in the critically ill. Anaesth Intensive Care 30 (2002), 134–144.
7. [7] Overington, J.P., Al-Lazikani, B., Hopkins, A.L., How many drug targets are there?. Nat Rev Drug Discov 5 (2006), 993–996.
8. [8] Gonçalves-Pereira, J., Póvoa, P., Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams. Crit Care, 15, 2011, R206.
9. [9] Scaglione, F., Paraboni, L., Pharmacokinetics/pharmacodynamics of antibacterials in the intensive care unit: setting appropriate dosing regimens. Int J Antimicrob Agents 32 (2008), 294–301.
10. [10] Mehrotra, R., Gaudio, R., Palazzo, M., Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness. Intensive Care Med 30 (2004), 2145–2156.
11. [11] Sime, F.B., Roberts, M.S., Peake, S.L., Lipman, J., Roberts, J.A., Dose β-lactam pharmacokinetic variability in critically ill patients justify therapeutic drug monitoring? A systematic review. Ann Intensive Care, 2, 2012, 35.
12. [12] Abdul-Aziz, M.H., Dulhunty, J.M., Bellomo, R., Lipman, J., Roberts, J.A., Continuous β-lactam infusion in critically ill patients: the clinical evidence. Ann Intensive Care, 2, 2012, 37.
13. [13] Taccone, F.S., Laterre, P.F., Dugernier, T., Spapen, H., Delattre, I., Wittebole, X., et al. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care, 14, 2010, R126.
14. [14] Roberts, J.A., Kirkpatrick, C.M.J., Roberts, M.S., Robertson, T.A., Dalley, A.J., Lipman, J., Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 64 (2009), 142–150.
15. [15] Ikawa, K., Norikawa, N., Ikeda, K., Miki, M., Kobayashi, M., Population pharmacokinetics and pharmacodynamics of meropenem in Japanese pediatric patients. J Infect Chemother 16 (2010), 139–143.
16. [16] Smith, P.B., Cohen-Wolkowiez, M., Castro, L.M., Poindexter, B., Bidegain, M., Weitkamp, J., et al. Population pharmacokinetics of meropenem in plasma and cerebrospinal fluid of infants with suspected or complicated intra-abdominal infections. Pediatr Infect Dis J 30 (2011), 844–849.
17. [17] Goldstein, B., Giroir, B., Randolph, A., International Pediatric Sepsis Consensus Conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 6 (2005), 2–8.
18. [18] Kipper, K., Anier, K., Leito, I., Karjagin, J., Oselin, K., Herodes, K., Rapid determination of meropenem in biological fluids by LC: comparison of various methods for sample preparation and investigation of meropenem stability. Chromatographia 70 (2009), 1423–1427.
19. [19] Clinical and Laboratory Standards Institute, Performance standards for antimicrobial susceptibility testing; twentieth-first informational supplement. 2011, CLSI, Wayne (PA) Document M100-S21.
20. [20] European Committee on Antimicrobial Susceptibility Testing, Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0. http://www.eucast.org, 2016 [accessed 25.05.16].
21. [21] Jaruratanasirikul, S., Sriwiriyajan, S., Punyo, J., Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother 49 (2005), 1337–1339.
22. [22] Kiratisin, P., Chongthaleong, A., Tan, T.Y., Lagamayo, E., Roberts, S., Garcia, J., et al. Comparative in vitro activity of carbapenems against major Gram-negative pathogens: results of Asia-Pacific surveillance from the COMPACT II study. Int J Antimicrob Agents 39 (2012), 311–316.
23. [23] Mouton, J.W., den Hollander, J.G., Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 38 (1994), 931–936.